Prana Biotechnology Ltd (PRAN) 1.09 $PRAN
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:45AM CST
CYTK: 7.78 (+1.29), MNOV: 3.62 (-0.56), MX: 7.52 (-7.50), SIEB: 1.71 (-0.24), QKLS: 2.10 (-0.24), YUMA: 1.88 (+0.67), CYBR: 52.52 (+6.83), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), CECO: 5.34 (-0.92), GENE: 8.04 (+1.90), SGNL: 3.91 (+2.15), IMI: 1.70 (-0.20), RCKY: 18.43 (+4.33), WAC: 20.29 (+2.57), FNJN: 2.77 (-0.36), ZNGA: 2.24 (-0.42), PRAN: 1.09 (-0.55)
Prana sinks on partial clinical hold of Huntington's disease trial
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 9:29AM CST
PRAN: 1.09 (-0.55)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:15AM CST
CYTK: 7.78 (+1.29), HK: 2.18 (-0.02), CYBR: 52.52 (+6.83), FXEN: 1.99 (+0.10), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), SDRL: 12.32 (-0.70), MTSN: 4.04 (+0.19), BLDP: 2.66 (-0.26), GDP: 3.58 (+0.29), REXX: 5.08 (+0.13), DNR: 8.66 (+0.39), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96), SD: 2.09 (+0.14), MX: 7.52 (-7.50), KN: 18.59 (-3.05), GENE: 8.04 (+1.90), VDSI: 27.86 (+2.69), IDRA: 4.10 (-0.14), SFY: 2.91 (+0.26), ARIA: 7.35 (+0.45), FSL: 37.53 (+2.83), PRAN: 1.09 (-0.55), OAS: 16.84 (-0.03)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), PRAN: 1.09 (-0.55), PTIE: 2.05 (+0.03), CUR: 3.41 (+0.13)
The Lancet Neurology Publishes Prana's Huntington Disease Trial
Business Wire - Wed Nov 19, 10:00AM CST
Prana Biotechnology (ASX
BT)(NASDAQ RAN) has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world's leading medical journals, The Lancet Neurology.
PBT: 10.19 (-0.13), PRAN: 1.09 (-0.55)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 9.05 (-0.40), TEVA: 56.77 (-0.58), ASPX: 65.76 (+2.76), GSK: 47.94 (+1.99), PRAN: 1.09 (-0.55), VRX.TO: 207.95 (-1.47)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 391.66 (-0.45), MNOV: 3.62 (-0.56), CHTP: 6.52 (-0.03), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), BCLI: 3.86 (-0.02), BSX: 14.98 (+0.24), IPXL: 39.51 (+0.69), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), CVTS: (), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), PRTA: 22.89 (+0.13), PRAN: 1.09 (-0.55), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Brain Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnncfl/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Neuralstem, Inc. - Bionomics Limited - Critical Outcome Technologies Inc. - Prana Biotechnology Limited - e-Therapeutics plc - AngioChem Inc. - Merrimack Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Kinex Pharmaceuticals, LLC - Nuvilex, Inc. - TAU Therapeutics, LLC - CureFAKtor Pharmaceuticals. LLC - Arrien Pharmaceuticals, LLC - Oncology Research International Limited For more information visit http://www.researchandmarkets.com/research/nn...ain_cancer
MACK: 10.22 (+0.40), STML: 14.07 (-0.10), PRAN: 1.09 (-0.55), CUR: 3.41 (+0.13)
Horizon Pharma's Actimmune Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 1:00PM CDT
Horizon Pharma plc's (HZNP) Actimmune received orphan drug status in the U.S. for the treatment of neuro-muscular genetic disorder, Friedreich's ataxia (FA).
MNK: 115.01 (+2.51), ACT: 285.37 (+3.71), HZNP: 16.84 (-0.41), PRAN: 1.09 (-0.55)
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma
PR Newswire - Thu Sep 11, 8:15AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.25, up 0.67%, with the index gaining 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), CytRx Corporation (NASDAQ: CYTR), Insmed Inc. (NASDAQ: INSM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research on these five companies can be accessed at:
DVAX: 16.96 (+0.66), INSM: 17.40 (+0.69), VRTX: 113.66 (+4.03), CYTR: 2.96 (+0.23), PRAN: 1.09 (-0.55)
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
AGN: 229.49 (+1.87), GILD: 101.90 (+1.10), PRAN: 1.09 (-0.55)
Why Prana Biotechnology (PRAN) Stock Is Surging Today
at The Street - Fri Sep 05, 8:46AM CDT
Shares of Prana Biotechnology (PRAN) soared 26.17% to $2.70 in morning trading Friday after the company announced the FDA granted Orphan Drug designation to PBT2 to treat Huntington Disease.
PRAN: 1.09 (-0.55)
Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease
PR Newswire - Fri Sep 05, 6:45AM CDT
Prana Biotechnology (ASX: PBT) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease.
PBT: 10.19 (-0.13), PRAN: 1.09 (-0.55)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Aug 29, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
ECYT: 5.26 (-0.02), ALIM: 5.16 (unch), PRAN: 1.09 (-0.55)
Prana Alzheimer's disease Development Program update
PR Newswire - Thu Jul 17, 3:10PM CDT
Prana Biotechnology (NASDAQ: PRAN; ASX: PBT) has today provided an update on its clinical development program for Alzheimer's disease.
PRAN: 1.09 (-0.55)
Investors look to Lighten Up on Shares of Prana Biotechnology, Shares Down 8.5% (PRAN)
Comtex SmarTrend(R) - Tue Jul 15, 11:40AM CDT
Prana Biotechnology (NASDAQ RAN) is one of today's worst performing low-priced stocks, down 8.5% to $2.26 on 1.0x average daily volume. Prana Biotechnology has traded 1.3 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-8.5% to the Dow's -0.1%) and underperformed the S&P 500 (-8.5% to the S&P's -0.4%) during today's trading.
PRAN: 1.09 (-0.55)
Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics
PR Newswire - Mon Jul 14, 6:04AM CDT
On Friday, July 11, 2014, the NASDAQ Composite ended at 4,415.49, up 0.44%, the Dow Jones Industrial Average advanced 0.17%, to finish the day at 16,943.81, and the S&P 500 closed at 1,967.57, up 0.15%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.90, up 0.14%, with the index also advancing 10.01% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Prana Biotechnology Ltd (NASDAQ: PRAN), Isis Pharmaceuticals Inc. (NASDAQ: ISIS) and Pharmacyclics Inc. (NASDAQ: PCYC). Free technical research on ONVO, PRAN, ISIS and PCYC can be downloaded upon signing up at:
PCYC: 163.28 (+0.23), ISIS: 63.86 (-0.43), ONVO: 6.34 (+0.07), PRAN: 1.09 (-0.55)
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
AVNR: 16.96 (unch), DVA: 73.10 (-3.29), RPTP: 9.05 (-0.40), AERI: 27.91 (+0.14), PRAN: 1.09 (-0.55)
5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 11, 5:46AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
MPET: 0.84 (-0.03), BOTA: 2.60 (-0.06), WTSL: 0.03 (unch), PRAN: 1.09 (-0.55), WAVX: 0.73 (+0.02), NIHD: 0.06 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:45AM CST
CYTK: 7.78 (+1.29), MNOV: 3.62 (-0.56), MX: 7.52 (-7.50), SIEB: 1.71 (-0.24), QKLS: 2.10 (-0.24), YUMA: 1.88 (+0.67), CYBR: 52.52 (+6.83), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), CECO: 5.34 (-0.92), GENE: 8.04 (+1.90), SGNL: 3.91 (+2.15), IMI: 1.70 (-0.20), RCKY: 18.43 (+4.33), WAC: 20.29 (+2.57), FNJN: 2.77 (-0.36), ZNGA: 2.24 (-0.42), PRAN: 1.09 (-0.55)
Prana sinks on partial clinical hold of Huntington's disease trial
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 9:29AM CST
PRAN: 1.09 (-0.55)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:15AM CST
CYTK: 7.78 (+1.29), HK: 2.18 (-0.02), CYBR: 52.52 (+6.83), FXEN: 1.99 (+0.10), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), SDRL: 12.32 (-0.70), MTSN: 4.04 (+0.19), BLDP: 2.66 (-0.26), GDP: 3.58 (+0.29), REXX: 5.08 (+0.13), DNR: 8.66 (+0.39), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96), SD: 2.09 (+0.14), MX: 7.52 (-7.50), KN: 18.59 (-3.05), GENE: 8.04 (+1.90), VDSI: 27.86 (+2.69), IDRA: 4.10 (-0.14), SFY: 2.91 (+0.26), ARIA: 7.35 (+0.45), FSL: 37.53 (+2.83), PRAN: 1.09 (-0.55), OAS: 16.84 (-0.03)
Alzheimer's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcdctm/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 210 companies are cited in this text including: - AB Science - AbbVie Inc. - AC Immune SA - CHA Bio & Diostech Co., Ltd. - Chase Pharmaceuticals Corporation - Clera Inc. - Eli Lilly and Company - EncephRx, Inc. - EndoCeutics, Inc. - Epigen Biosciences, Inc. - MediPost Co., Ltd. - Neuralstem, Inc. - Pain Therapeutics, Inc. - PALUMED S.A. - Panacea Pharmaceuticals, Inc. - PeptiDream Inc. - Peptron, Inc. - Pfizer Inc. - PharmatrophiX, Inc. - Pharnext SAS - Phenomenome Discoveries, Inc. - PhysioGenix, Inc. - Plexxikon Inc. - Prana Biotechnology Limited - Probiodrug AG - Proteome Sciences Plc - Suven Life Sciences Ltd. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/xcdctm/alzheimers
PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), ABBV: 58.05 (+1.00), PRAN: 1.09 (-0.55), PTIE: 2.05 (+0.03), CUR: 3.41 (+0.13)
The Lancet Neurology Publishes Prana's Huntington Disease Trial
Business Wire - Wed Nov 19, 10:00AM CST
Prana Biotechnology (ASX
BT)(NASDAQ RAN) has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world's leading medical journals, The Lancet Neurology. PBT: 10.19 (-0.13), PRAN: 1.09 (-0.55)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 9.05 (-0.40), TEVA: 56.77 (-0.58), ASPX: 65.76 (+2.76), GSK: 47.94 (+1.99), PRAN: 1.09 (-0.55), VRX.TO: 207.95 (-1.47)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 391.66 (-0.45), MNOV: 3.62 (-0.56), CHTP: 6.52 (-0.03), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), BCLI: 3.86 (-0.02), BSX: 14.98 (+0.24), IPXL: 39.51 (+0.69), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), CVTS: (), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), PRTA: 22.89 (+0.13), PRAN: 1.09 (-0.55), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Brain Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnncfl/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Neuralstem, Inc. - Bionomics Limited - Critical Outcome Technologies Inc. - Prana Biotechnology Limited - e-Therapeutics plc - AngioChem Inc. - Merrimack Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Kinex Pharmaceuticals, LLC - Nuvilex, Inc. - TAU Therapeutics, LLC - CureFAKtor Pharmaceuticals. LLC - Arrien Pharmaceuticals, LLC - Oncology Research International Limited For more information visit http://www.researchandmarkets.com/research/nn...ain_cancer
MACK: 10.22 (+0.40), STML: 14.07 (-0.10), PRAN: 1.09 (-0.55), CUR: 3.41 (+0.13)
Horizon Pharma's Actimmune Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 1:00PM CDT
Horizon Pharma plc's (HZNP) Actimmune received orphan drug status in the U.S. for the treatment of neuro-muscular genetic disorder, Friedreich's ataxia (FA).
MNK: 115.01 (+2.51), ACT: 285.37 (+3.71), HZNP: 16.84 (-0.41), PRAN: 1.09 (-0.55)
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma
PR Newswire - Thu Sep 11, 8:15AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.25, up 0.67%, with the index gaining 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), CytRx Corporation (NASDAQ: CYTR), Insmed Inc. (NASDAQ: INSM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research on these five companies can be accessed at:
DVAX: 16.96 (+0.66), INSM: 17.40 (+0.69), VRTX: 113.66 (+4.03), CYTR: 2.96 (+0.23), PRAN: 1.09 (-0.55)
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
AGN: 229.49 (+1.87), GILD: 101.90 (+1.10), PRAN: 1.09 (-0.55)
Why Prana Biotechnology (PRAN) Stock Is Surging Today
at The Street - Fri Sep 05, 8:46AM CDT
Shares of Prana Biotechnology (PRAN) soared 26.17% to $2.70 in morning trading Friday after the company announced the FDA granted Orphan Drug designation to PBT2 to treat Huntington Disease.
PRAN: 1.09 (-0.55)
Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease
PR Newswire - Fri Sep 05, 6:45AM CDT
Prana Biotechnology (ASX: PBT) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease.
PBT: 10.19 (-0.13), PRAN: 1.09 (-0.55)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Fri Aug 29, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
ECYT: 5.26 (-0.02), ALIM: 5.16 (unch), PRAN: 1.09 (-0.55)
Prana Alzheimer's disease Development Program update
PR Newswire - Thu Jul 17, 3:10PM CDT
Prana Biotechnology (NASDAQ: PRAN; ASX: PBT) has today provided an update on its clinical development program for Alzheimer's disease.
PRAN: 1.09 (-0.55)
Investors look to Lighten Up on Shares of Prana Biotechnology, Shares Down 8.5% (PRAN)
Comtex SmarTrend(R) - Tue Jul 15, 11:40AM CDT
Prana Biotechnology (NASDAQ
RAN) is one of today's worst performing low-priced stocks, down 8.5% to $2.26 on 1.0x average daily volume. Prana Biotechnology has traded 1.3 million shares thus far today, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-8.5% to the Dow's -0.1%) and underperformed the S&P 500 (-8.5% to the S&P's -0.4%) during today's trading. PRAN: 1.09 (-0.55)
Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics
PR Newswire - Mon Jul 14, 6:04AM CDT
On Friday, July 11, 2014, the NASDAQ Composite ended at 4,415.49, up 0.44%, the Dow Jones Industrial Average advanced 0.17%, to finish the day at 16,943.81, and the S&P 500 closed at 1,967.57, up 0.15%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.90, up 0.14%, with the index also advancing 10.01% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Prana Biotechnology Ltd (NASDAQ: PRAN), Isis Pharmaceuticals Inc. (NASDAQ: ISIS) and Pharmacyclics Inc. (NASDAQ: PCYC). Free technical research on ONVO, PRAN, ISIS and PCYC can be downloaded upon signing up at:
PCYC: 163.28 (+0.23), ISIS: 63.86 (-0.43), ONVO: 6.34 (+0.07), PRAN: 1.09 (-0.55)
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
AVNR: 16.96 (unch), DVA: 73.10 (-3.29), RPTP: 9.05 (-0.40), AERI: 27.91 (+0.14), PRAN: 1.09 (-0.55)
5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 11, 5:46AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
MPET: 0.84 (-0.03), BOTA: 2.60 (-0.06), WTSL: 0.03 (unch), PRAN: 1.09 (-0.55), WAVX: 0.73 (+0.02), NIHD: 0.06 (-0.01)
